Journal article

Systematic review with meta-analysis: sirolimus-or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma

Sam E Grigg, Gino L Sarri, Paul J Gow, Neville D Yeomans

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | WILEY | Published : 2019

Abstract

BACKGROUND: Calcineurin-inhibitor immunosuppressants (tacrolimus and ciclosporin) have been associated with an exposure-related increase in tumour recurrence following liver transplantation for hepatocellular carcinoma (HCC). Conversely, mechanistic target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) have been suggested to reduce recurrence rates and improve survival in this patient group. AIM: To clarify the potential benefit of mTOR-inhibitors in HCC transplant patients by comparing recurrence and survival outcomes with calcineurin-inhibitor-based immunosuppression. METHODS: A systematic review and meta-analysis was performed. The inclusion criteria were observational or inter..

View full abstract